To the authors' knowledge, the practice patterns for patients aged more than 80 years with stage III non-small cell lung cancer (NSCLC) is not well known. The purpose of the current study was to investigate factors predictive of and the impact on overall survival (OS) after concurrent chemoradiation (CRT) among patients aged 80 years with American Joint Committee on Cancer stage III NSCLC in the National Cancer Data Base (NCDB). METHODS: In the NCDB, patients aged 80 years who were diagnosed with stage III NSCLC from 2004 to 2013 with complete treatment records were identified. Multivariable logistic regression and Cox proportional hazard models were generated and propensity score-matched analysis was used. RESULTS: A total of 12,641 patients met the entry criteria: 6018 (47.6%) had stage IIIA disease and 6623 (52.4%) had stage IIIB disease. The median age at the time of diagnosis was 83.0 years (range, 80-91 years). A total of 7921 patients (62.7%) received no therapy. Black race (odds ratio [OR], 1.23; 95% confidence interval [95% CI], 1.06-1.43) and living in a lower educated census tract of residence (OR, 1.20; 95% CI, 1.03-1.40) were found to be associated with not receiving care, whereas treatment at an academic center (OR, 0.80; 95% CI, 0.70-0.92) was associated with receiving cancer-directed therapy. Receipt of no treatment (hazard ratio [HR], 2.69; 95% CI, 2.57-2.82) or definitive radiation alone (HR, 1.15; 95% CI, 1.07-1.24) compared with CRT was associated with worse OS. On propensity score matching, not receiving CRT was found to be associated with worse OS (HR, 1.58; 95% CI, 1.44-1.72). CONCLUSIONS: In this NCDB analysis, approximately 62.7% of patients aged 80 years with stage III NSCLC received no cancer-directed care. Black race and living in a lower educated census tract were associated with not receiving cancer-directed care. OS was found to be improved in patients receiving CRT.
INTRODUCTION
Lung cancer is the most common cancer cause of death in the United States, with more than 158,000 patients dying annually. 1 The standard-of-care therapy for patients with stage III non-small cell lung cancer (NSCLC) is concurrent chemotherapy and radiotherapy (CRT), established in randomized clinical trials. [2] [3] [4] In the clinical trial setting, the median overall survival (OS) for patients with stage III NSCLC approaches 29 months. 5 To our knowledge, there is a lack of data regarding the use of CRT in octogenarians and nonagenarians, despite the fact that >36% of new lung cancers are diagnosed in patients aged 75 years. 1 These elderly patients may be undertreated and routinely are underrepresented on clinical trials for many reasons, including concerns of medical fragility, lower patient willingness to pursue aggressive therapy, or concerns regarding the usefulness of therapy in patients who may die of competing risk factors. 6, 7 Highlighting the lack of clarity, recent guidelines for the management of elderly patients with stage III lung cancer state that "chemoradiation, either sequentially or concurrently, can be considered an option in elderly patients although it should be only used in selected, fit patients. Data are limited in the elderly and should be considered with caution." 8 Given the rising number of patients with cancer who are aged 80 years 9 and the lack of information regarding the usefulness of CRT in this older population, we used the National Cancer Data Base (NCDB) to identify a large cohort of octogenarians and nonagenarians diagnosed with American Joint Committee on Cancer stage III NSCLC. The main goal of the current study was to identify patient and tumor factors associated with patients not receiving treatment and patients receiving CRT. The secondary objective was to determine the impact of the type of treatment received on OS.
MATERIALS AND METHODS

Patient Selection
The NCDB captures approximately 70% of newly diagnosed malignancies in the United States. It only includes cases diagnosed at facilities accredited by the Commission on Cancer, a program of the American College of Surgeons that recognizes centers for providing comprehensive, high-quality, and multidisciplinary patient-centered care. The NCDB includes detailed demographic, socioeconomic, disease, and treatment characteristics in addition to survival outcomes.
The NCDB regarding NSCLC was queried for patients diagnosed between 2004 and 2014. The inclusion criteria for the current study included only patients who were aged 80 years at the time of diagnosis, had invasive histology, and had no history of a previous cancer diagnosis. Patients with stage I or II disease or metastatic disease or those with incomplete treatment or survival records were excluded (see Supporting Information Fig. 1) . We focused on patients with stage III disease to homogenize the study population and focus specifically on the impact of CRT on survival. The final current study population was classified into those with clinical American Joint Committee on Cancer stage IIIA or IIIB disease, using modern criteria. 10 Treatment groups were those receiving no treatment, those receiving definitive radiation alone (defined as a minimum of 45 grays [Gy] to a thoracic volume), and those receiving CRT as the standard of care. The following patient characteristics were examined: age, sex, race (white, black, and other), comorbidities as quantified by the Charlson-Deyo Comorbidity Score, 11, 12 insurance status (Medicare, private, or not insured), county of residence (urban, rural, or metropolitan as defined by the US Census Bureau), percentage of residents without a high school degree in the patient's census tract of residence (<7%, 7%-12.9%, 13%-20%, and 21% quartiles), and median income of the patient's census tract of residence (<$38,000, $38,000-$47,999, $48,000-$62,999, and >$63,000 as determined by the American Community Survey). Census tracts are permanent subdivisions of a county that are updated by local participants before each national census, containing populations of between 1200 and 8000 individuals. The following tumor characteristics were examined: histology (squamous cell carcinoma, adenocarcinoma, or biopsy proven but not otherwise specified), grade (well/moderately differentiated and poorly differentiated), clinical T classification, clinical N classification, and overall clinical stage of disease (stage IIIA vs stage IIIB). The following treatment characteristics were examined: facility location (Northeast, South, Midwest, and West) and facility type (academic, comprehensive community cancer program, and community cancer program). Age was evaluated as a continuous variable after it was determined it had a linear effect on OS.
Statistical Analysis
Statistical analysis was conducted using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) and SAS macros. 13 Descriptive statistics for each variable were reported and compared across treatment groups using chi-square and analysis of variance tests when appropriate. Statistical models were described as follows.
Treatment models
The response variables were: 1) receipt of no treatment versus receipt of radiation alone or CRT; and 2) receipt of CRT versus all other treatment modalities (no treatment or radiation alone). Explanatory variables included race, sex, insurance status, income, education, Charlson-Deyo Comorbidity Score, histology, tumor grade, tumor stage, facility location, and facility type. Univariate logistic regression models were built for each explanatory variable. Multivariable models were built allowing the explanatory variables to remain in the model using backwards elimination with a P value for removal of .1. In addition, a multinomial logistic regression model was run comparing the 3 treatment groups and their association with patient, tumor, and treatment variables.
OS models
The response variable was OS, defined as months from the time of diagnosis to death or last follow-up, in which patients who did not die were censored at the time of last follow-up. Explanatory variables included race, sex, insurance status, education, Charlson-Deyo Comorbidity Score, histology, tumor grade, tumor stage, treatment type, facility location, and facility type. Univariate Cox proportional hazard models were built for each explanatory variable. Multivariable models were built by fixing treatment into each model, and allowing the other explanatory variables to remain in the model using backwards elimination with a P value for removal of .1. KaplanMeier curves were generated for OS stratified by Original Article treatment group, with comparisons made using log-rank tests. Two separate Cox proportional hazards models and Kaplan-Meier OS analyses were run, one of which included all patients and one in which patients who died within 6 months of diagnosis were excluded. This analysis was performed to reduce biases of the very ill who would be less likely to receive definitive therapy. Finally, propensity score matching was implemented to reduce treatment selection bias. A logistic regression model predicting for CRT versus other treatments was performed to estimate the propensity score of all covariates. Patients then were matched 1:1 based on the propensity score using a greedy 5:1 digit match algorithm.
14 After matching, the balance of the 2 groups was evaluated by standardized differences, with values <0.1 considered negligible. 15 The OS effect in the matched sample was estimated using a Cox model with a robust variance estimator. 16, 17 The collinearity among all variables was checked by removing variables with variance inflation factors >10; however, no variables included in the multivariable analyses were found to be too highly correlated. For each Cox survival model, the proportional hazard assumption was assessed by plotting the logarithms of the cumulative baseline hazard rate for each level of each covariate after adjusting for the effects of other variables. Time-dependent covariates also were considered by multiplying the log survival time by each covariate. A time-dependent P value >.05 suggested a valid proportional hazards assumption. For all analyses, a P value <.05 was considered to be statistically significant.
RESULTS
Patient Characteristics
A total of 12,641 patients met the study entry criteria (see Supporting Information Table 1 summarizes the remaining characteristics of the current study population.
Predictors of Receiving No Treatment
In total, 7921 patients (62.7%) received no therapy. On univariable analysis, older age, nonwhite race, receiving treatment in the Western region of the United States, female sex, living in a lower educated census tract, having adenocarcinoma histology, and having stage IIIB disease were factors associated with being more likely not to receive therapy whereas evaluation at an academic center was associated with receiving therapy (Table 1) . On multivariable analysis, older age, nonwhite race, living in a lower educated county, having adenocarcinoma histology, having poorly differentiated tumors, and having stage IIIB disease were associated with not receiving therapy, whereas treatment at an academic center, male sex, and having with a Charlson-Deyo Comorbidity Score of 0 were factors associated with being more likely to receive therapy ( Table 1) .
Predictors of Receiving CRT
In total, 3567 patients (28.2%) received CRT. On univariable analysis, older age, male sex, having a CharlsonDeyo Comorbidity Score of 0, living in an urban county, having nonadenocarcinoma histology, and being treated at a facility located in the non-Western United States were associated with receipt of CRT whereas nonwhite race and having stage IIIB disease were associated with lack of receipt of CRT (Table 2) . On multivariable analysis, male sex, a Charlson-Deyo Comorbidity Score of 0, living in an urban county, having nonadenocarcinoma histology, and receiving treatment at a facility located in the nonWestern United States were associated with receipt of CRT. In the same model, advancing age, black race, living in a lower educated county, and having stage IIIB disease were associated with lack of receipt of CRT (Table 2) . Multinomial logistic regression model results for variables associated with receipt of different therapies are reported in Supporting Information Table 2 , with age, race, sex, insurance status, Charlson-Deyo Comorbidity Score, tumor grade, tumor histology, tumor stage, facility location, and facility type all found to be statistically significant (all P<.01).
Overall Survival
Among all patients, 2-year OS estimates were 31.0% (95% confidence interval [95% CI], 29.4%-32.5%) in the CRT cohort compared with 23.6% (95% CI, 21.1%-26.1%) and 6.9% (95% CI, 6.3%-7.5%), respectively, in the cohort treated with definitive radiation alone and the cohort receiving no treatment (P<.01) (Fig. 1) . Among patients who survived at least 6 months from their diagnosis, 2-year OS estimates were 32.0% (95% CI, 30.2%-33.8%) in the CRT cohort compared with 24.4% (95% CI, 21.5%-27.4%) and 17.7% (95% CI, 16.1%-19.4%), respectively, in the cohort treated with definitive radiation alone and the cohort receiving no treatment (P<.01) (Fig. 2) . On univariable analysis of all patients, receiving no treatment or receiving definitive radiation alone (compared with CRT), older age, male sex, having nonadenocarcinoma histology, and having stage IIIB disease were associated with worse OS whereas having a CharlsonDeyo Comorbidity Score of 0, having well-differentiated tumors, and receiving treatment at an academic facility were associated with improved OS (Table 3) . On multivariable analysis of all patients, receipt of no treatment or definitive radiation alone was associated with worse OS compared with receipt of CRT. In the same model, advancing age, male sex, nonadenocarcinoma histology, and stage IIIB disease were associated with worse OS whereas patients with a Charlson-Deyo Comorbidity Score of 0, those with well-differentiated tumors, and those receiving treatment at an academic program were found to have improved OS (Table 3) . Supporting Information Table 3 details univariable and multivariable analyses of OS among patients who survived at least 6 months from their diagnosis.
After propensity score matching for all baseline variables, there were 1153 patients in the CRT group matched to 1153 patients who did not receive CRT. In this analysis, not receiving CRT was found to be associated with worse OS (hazard ratio, 1.58; 95% CI, 1.44-1.72) on Cox proportional hazard analysis. Two-year OS (Fig. 3) .
DISCUSSION
To the best of our knowledge, the current series is the largest in the literature examining octogenarians and nonagenarians with stage III NSCLC. Even in this older population, deviation from the standard of care of CRT was associated with worse OS. This OS benefit was confirmed when balancing for other demographic, socioeconomic, and disease variables, suggesting that the value of CRT is independent of age, race, comorbidity status, histology, and treatment facility characteristics in this NCDB series. Alarmingly, greater than one-half of octogenarians and nonagenarians with stage III lung cancer did not receive any care. Older age, black race, and living in a lower educated census tract were found to be risk factors for not receiving treatment. Conversely, male sex, treatment at an academic center, and improved comorbidity status were associated with receiving some form of therapy. Patients aged 80 years are seemingly underrepresented in the landmark clinical trials that established CRT as the standard of care for patients with stage III NSCLC. The Radiation Therapy Oncology Group (RTOG) 9410 trial was the landmark North American phase 3 trial comparing 2 different CRT regimens with sequential chemotherapy followed by radiation. 2 Patients were randomized to concurrent cisplatin and vinblastine with 63 Gy of thoracic radiation given daily, cisplatin and vinblastine followed by 63 Gy of thoracic radiation at day 50 (sequential therapy), or cisplatin and etoposide with 69.6 Gy of thoracic radiation given twice daily. The 5-year OS rate was improved in patients receiving concurrent cisplatin and vinblastine with radiation compared with sequential therapy, with rates of 16% and 10%, respectively. OS was statistically improved in the treatment arm of concurrent cisplatin and vinblastine and radiation compared with the concurrent cisplatin and etoposide and twice-daily radiation arm, with a hazard ratio of 0.93. 2 RTOG 9410 dramatically influenced practice, and CRT became the standard of care for medically fit patients with stage III lung cancer. However, its applicability for octogenarians and nonagenarians is unclear. This trial did not have an upper limit cutoff value for age enrollment, but closer examination demonstrated a minimal number of patients aged 80 years. In fact, the maximum age of enrolled patients on the 2 vinblastine arms was 79 years and the maximum age of enrolled patients on the etoposide arm was 80 years. The limited enrollment of patients aged 80 years also was observed in a more recently published 2-by-2 factorial phase 3 trial, RTOG 0617. This trial investigated the efficacy of dose escalation of thoracic radiation of 60 Gy versus 74 Gy with concurrent chemotherapy with carboplatin and paclitaxel. 5 The RTOG 0617trial found that the median OS was improved in patients receiving standard-dose radiation compared with high-dose radiation, with rates of 28.7 months compared with 20.3 months, respectively. This trial did accrue more octogenarians, with the eldest patient being aged 83 years. However, the median age of the enrolled patients was 64 years, suggesting that the number of octogenarians was a relatively small percentage of this trial population. 5 The limited number of patients aged 80 years on these 2 landmark trials, as well as most randomized phase 3 lung cancer trials, 7 is likely multifactorial. There are concerns regarding aggressive therapies causing excessive toxicity in an older cohort, elderly patients themselves choosing less aggressive therapy, and the usefulness of therapy in patients with worsening performance status and medical comorbidities. 7, 8, [18] [19] [20] [21] Given these concerns regarding aggressive chemoradiation in an elderly population, targeted agents and immunotherapy also play a role in therapy. Although typically reserved for patients with metastatic disease, recent reports have indicated that the incidence of molecular mutations appears congruent between patients with early-stage and late-stage disease. [22] [23] [24] [25] In addition, there are ongoing clinical trials examining the impact of targeted agents and/or immunotherapy in the upfront nonmetastatic setting. [26] [27] [28] Depending on these outcomes, these agents would be useful in an elderly population because their side effect profile generally is more favorable than that of traditional cytotoxic chemotherapy. 29, 30 The results of the current study also confirmed known sociodemographic factors affecting OS in patients with lung cancer in a geriatric population. Male sex was associated with lower OS in the current series, a finding that is similar to other large reviews of nationwide cancer mortality. 31 Stage IIIB (vs stage IIIA) disease was associated with worse OS, which further validates the impact of modern staging criteria on prognosis.
10 A Charlson-Deyo Comorbidity Score of 0 was associated with higher OS in the current series, confirming that lack of medical comorbidities confers improved prognosis 11, 12 in elderly patients. Perhaps the most alarming finding herein was that a significant percentage of patients received no therapy at all. Other population-based efforts in lung cancer, mostly derived from Surveillance, Epidemiology, and End Results-Medicare databases, have estimated that between 34% to 44% of elderly patients (with varying definitions) do not receive therapy. 32, 33 Large database studies in other disease sites also have shown that elderly patients are less likely to undergo therapy. 34 The higher rate of receipt of no therapy in the current study is especially concerning because all patients in our series had health insurance, which has been known to impact clinical outcomes. 35, 36 Despite an insured population, socioeconomic barriers still appeared to influence the receipt of care, with black patients found to be 23% more likely and patients living in a lower educated census tract found to be 20% more likely to not receive cancer-directed therapy, which also has been shown to affect general mortality rates in geriatric adults. 37 To the best of our knowledge, the current study also is the first to confirm in a population of elderly patients with lung cancer that those patients treated at an academic center were more likely to receive CRT and experience improved OS, which previous series have suggested in younger populations. 38, 39 The current study series has several strengths and limitations. The major strength of this series was its sample size; to the best of our knowledge, it is the largest study conducted to date of octogenarians and nonagenarians with stage III NSCLC. Because the NCDB captures approximately 70% of new cancer diagnoses and includes many community centers, the elderly population in the current study is representative of a broad demographic, with treatment delivery and outcomes representative of the cancer community at large. However, similar to other studies from cancer registries, not all variables were captured, which may lead to an imbalance of the treatment groups, despite multivariable stratified analysis and propensity score-matched analysis. The benefit of receiving standard-of-care CRT persisted in all models, but confounding variables still may be present. Use of census tract estimates for socioeconomic variables introduces a possible fallacy because we do not have the information regarding these variables at the individual patient level. Particularly important in elderly patients, treatment toxicity information is not captured in the NCDB, and we were unable to comment on treatment toxicity in the current study. CRT is known to be associated with fibrosis, esophagitis, myelosuppression, and cardiac damage, 2, 5, 32, 40 and to our knowledge it is unclear whether elderly patients can withstand concurrent therapy routinely. Last, the NCDB does not provide information regarding cause of death, and it is possible that the benefit of CRT observed with regard to OS may be due to competing risks of mortality in this elderly population, although the Charlson-Deyo Comorbidity Score and propensity score matching testing were used to help account for competing risks of death.
Conclusions
In this analysis of the NCDB, >62% of octogenarians and nonagenarians diagnosed with stage III NSCLC did not receive cancer-directed therapy. Patients who received the standard of care of CRT were found to have improved OS compared with those who did not. This benefit persisted when patients were matched for socioeconomic, demographic, tumor, and treatment facility characteristics. Alarmingly, despite the current study encompassing an entirely insured population, we found that black race and living in a lower educated county were associated with not receiving therapy. Patients treated at an academic center were more likely to receive some form of cancerdirected therapy. Further efforts to limit health care disparities in these elderly patients needs to be investigated. 
